Odyssey Health announced that it has closed a definitive sub‑license agreement with its wholly‑owned subsidiary, Odyssey Medical Devices, Inc., granting the company exclusive worldwide marketing and distribution rights for the BreastCheck at‑home breast‑cancer screening device. BreastCheck is a non‑invasive, 15‑minute test that measures temperature differentials in the breast to identify potential abnormalities and is already registered with the U.S. Food and Drug Administration, the European Union, and the United Kingdom.
The deal marks the first step toward generating revenue for Odyssey, which has historically reported no sales. Commercial sales of BreastCheck are expected to begin in the second half of 2026, giving the company a direct channel to capture recurring usage from patients who may otherwise skip annual mammograms. By securing exclusive distribution rights, Odyssey removes a key regulatory hurdle and positions itself to benefit from the growing global breast‑cancer screening market, estimated at roughly $26 billion.
"With the addition of BreastCheck™, we are advancing our strategic transition toward revenue‑generating commercial products with recurring revenue potential," said Michael Redmond, President and CEO of Odyssey. "We believe this agreement provides a clear pathway to near‑term revenue, with commercial sales anticipated to commence in the second half of the year. This milestone significantly strengthens our portfolio and supports our long‑term growth strategy."
The market reacted positively to the announcement, driven by the combination of exclusive worldwide rights, regulatory approvals in the U.S., EU, and UK, and the product’s at‑home, rapid‑result design. Investors viewed the deal as a tangible step toward monetization for a company that has previously relied on external financing.
Odyssey has historically relied on a dilutive Mast Hill financing facility to fund its development activities. The BreastCheck agreement could reduce the company’s dependence on that facility and potentially unlock new capital, providing a more sustainable financial foundation as it transitions from a development‑stage entity to a revenue‑generating medtech business.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.